THE SGLT2 INHIBITOR EMPAGLIFLOZIN IMPROVES DIASTOLIC FUNCTION IN A HEART FAILURE MODEL MEDIATED VIA ENHANCED MYOCARDIAL KETONE METABOLISM | Publicación